Quit talking me into it Well the stock isn't what one would call cheap. Forget what their patent position is, although for these non-absorbable drugs that may be somewhat less relevant (cf. Vancocin). Summer Street's Jon Stephenson has been a consistent bull and he's been right to date. Peter